| Autor: |
Chatterjee, A., Meller, R., Nagpal, P., Schisler, J.C., Grabham, P., Cerqueira, B., Yousey, A., Aykin-Burns, N., Mason, C.E., Harris, A.D., Pearson, A.N., Foox, J., Aunins, T.R., Meydan, C., Galeano, D., Dybas, J.M., Vanderburg, C., Saravia-Butler, A., Singh, U., Sharma, S., Wallace, D.C., Costes, S.V., Singh, L.N., Enguita, F.J., Bowman, N.M., Sajadi, M.M., Moraes-Vieira, P.M., Griffin, R.J., Meinig, S.L., Wolfgang, M.C., Baylin, S.B., Emmett, M.R., Guarnieri, J.W., Altinok, S., Mozsary, C., Sapoval, N., Zaksas, V., McDonald, J.T., Davanzo, G.G., Wurtele, E.S., Treangen, T.J., Taylor, D., Corry, P.M., Beheshti, A., Priebe, W., Paccanaro, A., Hagan, R.S., UNC COVID-19 Pathobiology Consortium, Clement, J. |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| DOI: |
10.17615/cm13-py86 |
| Popis: |
MicroRNAs (miRNAs) are small non-coding RNAs involved in post-transcriptional gene regulation that have a major impact on many diseases and provide an exciting avenue toward antiviral therapeutics. From patient transcriptomic data, we determined that a circulating miRNA, miR-2392, is directly involved with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) machinery during host infection. Specifically, we show that miR-2392 is key in driving downstream suppression of mitochondrial gene expression, increasing inflammation, glycolysis, and hypoxia, as well as promoting many symptoms associated with coronavirus disease 2019 (COVID-19) infection. We demonstrate that miR-2392 is present in the blood and urine of patients positive for COVID-19 but is not present in patients negative for COVID-19. These findings indicate the potential for developing a minimally invasive COVID-19 detection method. Lastly, using in vitro human and in vivo hamster models, we design a miRNA-based antiviral therapeutic that targets miR-2392, significantly reduces SARS-CoV-2 viability in hamsters, and may potentially inhibit a COVID-19 disease state in humans. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
